Daré Bioscience secures $15M common stock purchase facility with Lincoln Park Capital

Dare Bioscience, Inc.

Entered $15M common stock purchase agreement with Lincoln Park Capital Fund, LLC.
Daré has sole discretion to sell up to $15M shares over 24 months; LPC obligated to buy at market-based prices.
Proceeds intended to help fund Phase 3 program for Sildenafil Cream, 3.6% (estimated $15M direct costs).
Issued 137,614 commitment shares to LPC; no warrants issued, no short selling permitted.
Daré may terminate agreement at any time with no cost or penalty.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.